Active substance
Trimethobenzamide
- US FDA 14
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TIGAN | 100MG/ML | injectable · injection | PH HEALTH | Prescription | 12 Jul 1974 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 300MG | capsule · oral | LUPIN | Prescription | 20 Aug 2003 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 300MG | capsule · oral | HERITAGE PHARMA AVET | Prescription | 21 Nov 2023 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | BPI LABS | Prescription | 16 Oct 2025 |
| TIGAN | 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | KING PHARMS LLC | Discontinued | 12 Jul 1974 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | WATSON LABS | Discontinued | 19 Oct 1982 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | WATSON LABS | Discontinued | 28 Dec 1982 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | HOSPIRA | Discontinued | 3 Apr 1987 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 300MG | capsule · oral | SUN PHARM INDUSTRIES | Discontinued | 28 Aug 2003 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE | 100MG/ML | injectable · injection | AM REGENT | Discontinued | 8 Mar 2011 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | AM REGENT | Discontinued | 8 Mar 2011 |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | SMITH AND NEPHEW | Discontinued | |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | SMITH AND NEPHEW | Discontinued | |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | 100MG/ML | injectable · injection | SOLOPAK | Discontinued |
Safety signals and safety-related labeling changes
- US FDA 13 Mar 2017 TIGAN — safety-related labeling change
Labeling sections changed: Contraindications; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.